Literature DB >> 29401118

How does abatacept really work in rheumatoid arthritis?

Michael Bonelli1, Clemens Scheinecker.   

Abstract

PURPOSE OF REVIEW: The purpose of this review is to summarize the current knowledge concerning the mechanisms of action of Abatacept in patients with rheumatoid arthritis. RECENT
FINDINGS: Abatacept (CTLA-4Ig) represents a soluble, recombinant, fully humanized fusion protein, comprising the extracellular domain of CTLA-4 and the Fc portion of IgG1. Abatacept binds to the costimulatory molecules CD80 and CD86 on antigen-presenting cells (APC), thereby blocking interaction with CD28 on T cells. In humans, Abatacept treatment was shown to be effective in patients with various autoinflammatory diseases including rheumatoid arthritis. Although the prevention of T-cell activation by interfering with signaling via CD28 still represents the main mechanism of action Abatacept acts on additional cell populations including regulatory T cells (Treg), monocytes/macrophages, osteoclasts, and B cells.
SUMMARY: Effects of Abatacept on other cell populations besides T cells have to be taken into account and might represent a valuable contribution to the therapeutic success.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29401118     DOI: 10.1097/BOR.0000000000000491

Source DB:  PubMed          Journal:  Curr Opin Rheumatol        ISSN: 1040-8711            Impact factor:   5.006


  14 in total

1.  Abatacept is Efficacious in the Treatment of Older Patients with csDMARD-Refractory Rheumatoid Arthritis: A Prospective, Multicenter, Observational Study.

Authors:  Sei Muraoka; Zento Yamada; Mai Kawazoe; Wataru Hirose; Hajime Kono; Shinsuke Yasuda; Yukiko Komano; Hiroshi Kawano; Toshihiko Hidaka; Shusaku Nakashima; Tsuyoshi Kasama; Tamio Teramoto; Toshihiro Nanki
Journal:  Rheumatol Ther       Date:  2021-08-26

2.  Construction of a ceRNA Network Related to Rheumatoid Arthritis.

Authors:  Zhanya Huang; Nanzhen Kuang
Journal:  Genes (Basel)       Date:  2022-04-06       Impact factor: 4.141

3.  Potential of regulatory T-cell-based therapies in the management of severe COVID-19.

Authors:  Emmanuel Stephen-Victor; Mrinmoy Das; Anupama Karnam; Bruno Pitard; Jean-François Gautier; Jagadeesh Bayry
Journal:  Eur Respir J       Date:  2020-09-03       Impact factor: 16.671

4.  The Association Between CTLA-4, CD80/86, and CD28 Gene Polymorphisms and Rheumatoid Arthritis: An Original Study and Meta-Analysis.

Authors:  Weixi Liu; Zhicheng Yang; Yan Chen; Haoyu Yang; Xiaoxian Wan; Xindie Zhou; Ruiping Liu; Yunkun Zhang
Journal:  Front Med (Lausanne)       Date:  2021-02-02

Review 5.  Recent Advances in Understanding the Pathogenesis of Rheumatoid Arthritis: New Treatment Strategies.

Authors:  Anna-Lena Mueller; Zahra Payandeh; Niloufar Mohammadkhani; Shaden M H Mubarak; Alireza Zakeri; Armina Alagheband Bahrami; Aranka Brockmueller; Mehdi Shakibaei
Journal:  Cells       Date:  2021-11-04       Impact factor: 6.600

6.  Humoral and cellular responses to spike of δ SARS-CoV-2 variant in vaccinated patients with immune-mediated inflammatory diseases.

Authors:  Linda Petrone; Andrea Picchianti-Diamanti; Gian Domenico Sebastiani; Alessandra Aiello; Bruno Laganà; Gilda Cuzzi; Valentina Vanini; Gina Gualano; Alba Grifoni; Mario Ferraioli; Concetta Castilletti; Silvia Meschi; Francesco Vaia; Emanuele Nicastri; Alessandro Sette; Delia Goletti
Journal:  Int J Infect Dis       Date:  2022-04-22       Impact factor: 12.074

Review 7.  B cells in autoimmune hepatitis: bystanders or central players?

Authors:  Christoph Schultheiß; Silja Steinmann; Ansgar W Lohse; Mascha Binder
Journal:  Semin Immunopathol       Date:  2022-04-29       Impact factor: 11.759

8.  Abatacept downregulates Fcγ receptor I on circulating monocytes: a potential therapeutic mechanism in patients with rheumatoid arthritis.

Authors:  Ryosuke Fukue; Yuka Okazaki; Takahisa Gono; Masataka Kuwana
Journal:  Arthritis Res Ther       Date:  2022-08-13       Impact factor: 5.606

9.  Abatacept as a Therapeutic Option for Rheumatoid Vasculitis.

Authors:  Layth Al Attar; Timothy Shaver
Journal:  Cureus       Date:  2018-04-19

10.  CTLA4-Ig treatment induces M1-M2 shift in cultured monocyte-derived macrophages from healthy subjects and rheumatoid arthritis patients.

Authors:  Maurizio Cutolo; Stefano Soldano; Emanuele Gotelli; Paola Montagna; Rosanna Campitiello; Sabrina Paolino; Carmen Pizzorni; Alberto Sulli; Vanessa Smith; Samuele Tardito
Journal:  Arthritis Res Ther       Date:  2021-12-24       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.